Athira Pharma Announces Reverse Stock Split to Enhance Marketability

Core Points - Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on therapies for neurodegenerative diseases [1] - A reverse stock split will occur on September 18, 2025, consolidating shares at a ratio of 1-for-10, approved by stockholders [1][2] - The reverse stock split aims to enhance the stock's marketability and potentially attract more investors [1][4] Stock Performance - Currently, ATHA's stock is priced at $0.38, with a slight increase of 0.29% or $0.0011 [3] - The stock has shown volatility, with a low of $0.35 and a high of $0.40 on the current trading day [3] - Over the past year, ATHA's stock has fluctuated between a high of $0.83 and a low of $0.22 [3] Market Capitalization and Trading Volume - Athira Pharma's market capitalization is approximately $15.1 million [4] - The trading volume on the NASDAQ exchange is 586,605 shares [4] - The reverse stock split may reduce the number of shares outstanding, potentially increasing the stock price [4]